Literature DB >> 1856263

Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg----Cys) results from a combination of decreased messenger ribonucleic acid levels and impairment of receptor function.

M Marcelli1, W D Tilley, S Zoppi, J E Griffin, J D Wilson, M J McPhaul.   

Abstract

Analysis of the nucleotide sequence of the coding segment of the androgen receptor gene in a patient (N105) with the receptor-negative form of complete testicular feminization has revealed a single substitution (CGC----TGC) at nucleotide 2476. This alteration results in the conversion of an arginine at amino acid 772 to a cysteine. Introduction of this mutation into an androgen receptor cDNA and transfection of the mutant cDNA into COS cells result in the production of a receptor protein with an alteration in the apparent Kd of ligand binding (3 nM) compared to that of the normal androgen receptor (0.5 nM). The mutant receptor protein predicted for patient N105 also demonstrates thermal instability of ligand binding that is not associated with quantitative or qualitative changes in the immunoreactive androgen receptor protein. When assayed in cotransfection experiments using a mouse mammary tumor virus-chloramphenicol acetyl transferase reporter system, the N105 receptor protein appears to be about a tenth as active as the control receptor. These functional characteristics do not appear sufficient to account for the phenotype of complete testicular feminization and do not explain the profound deficiency of androgen receptor in cultured skin fibroblasts. Quantitative S1 nuclease protection assays reveal that the level of androgen receptor mRNA in fibroblasts from patient N105 is markedly reduced. These results suggest that the phenotype in patient N105 is due to two effects of the nucleotide substitution at residue 2476: the replacement of a crucial amino acid (772) in the hormone-binding domain that impairs the function of any receptor molecules formed and a decrease in the level of androgen receptor mRNA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856263     DOI: 10.1210/jcem-73-2-318

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Mutations in the ligand-binding domain of the androgen receptor gene cluster in two regions of the gene.

Authors:  M J McPhaul; M Marcelli; S Zoppi; C M Wilson; J E Griffin; J D Wilson
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 2.  Molecular basis of androgen resistance.

Authors:  M Marcelli; W D Tilley; S Zoppi; J E Griffin; J D Wilson; M J McPhaul
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

Review 3.  Cell-based assays for screening androgen receptor ligands.

Authors:  Carmela Campana; Vincenzo Pezzi; William E Rainey
Journal:  Semin Reprod Med       Date:  2015-06-02       Impact factor: 1.303

4.  Substitution of arginine-839 by cysteine or histidine in the androgen receptor causes different receptor phenotypes in cultured cells and coordinate degrees of clinical androgen resistance.

Authors:  L K Beitel; P Kazemi-Esfarjani; M Kaufman; R Lumbroso; A M DiGeorge; D W Killinger; M A Trifiro; L Pinsky
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

5.  Molecular features and clinical phenotypes in androgen insensitivity syndrome in the absence and presence of androgen receptor gene mutations.

Authors:  P M Holterhus; R Werner; U Hoppe; J Bassler; E Korsch; M B Ranke; H G Dörr; O Hiort
Journal:  J Mol Med (Berl)       Date:  2005-11-11       Impact factor: 4.599

Review 6.  Gender verification in competitive sports.

Authors:  J L Simpson; A Ljungqvist; A de la Chapelle; M A Ferguson-Smith; M Genel; A S Carlson; A A Ehrhardt; E Ferris
Journal:  Sports Med       Date:  1993-11       Impact factor: 11.136

7.  Complete testicular feminization caused by an amino-terminal truncation of the androgen receptor with downstream initiation.

Authors:  S Zoppi; C M Wilson; M D Harbison; J E Griffin; J D Wilson; M J McPhaul; M Marcelli
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 8.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.